BerandaIMM • ASX
add
Immutep Ltd
Tutup sebelumnya
$0,045
Rentang hari
$0,050 - $0,069
Rentang tahun
$0,028 - $0,47
Kapitalisasi pasar
80,91Â jt AUD
Volume Rata-Rata
16,46Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
ASX
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (AUD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 3,01Â jt | 91,46% |
Biaya operasional | 2,71Â jt | 28,25% |
Penghasilan bersih | -22,43Â jt | -100,47% |
Margin laba bersih | -744,36 | -4,70% |
Penghasilan per saham | — | — |
EBITDA | -22,45Â jt | -76,87% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (AUD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 99,13Â jt | -37,76% |
Total aset | 147,20Â jt | -19,27% |
Total liabilitas | 48,30Â jt | 390,07% |
Total ekuitas | 98,90 jt | — |
Saham yang beredar | 1,47 M | — |
Harga terhadap nilai buku | 0,64 | — |
Tingkat pengembalian aset | -39,08% | — |
Tingkat pengembalian modal | -57,47% | — |
Arus Kas
Perubahan kas bersih
| (AUD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -22,43Â jt | -100,47% |
Kas dari operasi | -14,32Â jt | -0,36% |
Kas dari investasi | 17,66Â jt | 156,22% |
Kas dari pembiayaan | -56,28Â rb | 73,65% |
Perubahan kas bersih | 2,67Â jt | 106,07% |
Arus kas bebas | -13,87Â jt | -65,55% |
Tentang
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
CEO
Didirikan
2001
Situs
Karyawan
19
